While breast cancer patients generally expect the possibility of chemo hair loss, many are left unprepared for the potential permanent hair loss linked with Taxotere.

Indeed, for the most part, cancer patients generally expect that their hair will grow back after their chemotherapy treatment is over.

Instead, many patients have suffered from permanent chemo hair loss, or alopecia, after being treated with chemotherapy drugs like Taxotere.

One such cancer patient, Lisa B. is a South Carolina resident, and alleges in a Taxotere lawsuit that she suffered from permanent chemo hair loss as a result of treatment with Taxotere.

According to her lawsuit, Lisa underwent chemotherapy treatment with Taxotere between October 2013 and March 2014.

While they were aware of temporary hair loss during chemo, neither Lisa nor her doctors were aware of the possibility of permanent hair loss associated with Taxotere prior to undergoing treatment with the drug, the lawsuit claims.

The lawsuit alleges that in addition to alopecia from Taxotere, cancer patients who suffer from permanent hair loss suffer from mental anguish and economic damages.

After she realized her hair was never going to grow back, Lisa filed a Taxotere chemo hair loss lawsuit against Sanofi-Aventis. The lawsuit alleges that neither Lisa nor her healthcare providers had been informed about the severe and permanent Taxotere chemo hair loss risk.

The lawsuit was filed on a number of counts, including failure to warn, negligence, fraud, and punitive damages.

Taxotere Background

Taxotere is a chemotherapy treatment option manufactured and advertised by Sanofi-Aventis and approved as a breast cancer treatment drug by the U.S. Food and Drug Administration (FDA) back in May 1996.

Sanofi-Aventis has marketed Taxotere as a safe, effective, and superior drug treatment when compared to other chemotherapy drugs. However, prior to its approval, Taxotere had actually been recommended for rejection by the FDA in 1994 due to its toxicity.

Lawsuits claim that Sanofi-Aventis has been aware of reports and studies linking Taxotere to permanent hair loss after chemotherapy since as far back as its approval in 1996.

However, Taxotere lawsuits allege that, despite knowledge of their drug’s connection with permanent chemotherapy hair loss, Sanofi chose to conceal this information from patients and the medical community.

Lawsuits allege that because Sanofi-Aventis marketed Taxotere as similarly safe and effective to other chemotherapy drugs, despite the increased risk of alopecia, thousands of patients have been exposed to Taxotere’s side effects, including permanent Taxotere hair loss risk.

Permanent Taxotere Chemo Hair Loss Risk

Taxotere fights breast cancer by preventing cancer cells from growing, which in turn prevents the cancer from its ability to quickly spread. However, the same function that prevents the rapid growth of cancer cells may also prevent a patient’s hair from growing back after chemotherapy.

One of the most well-known side effects of chemotherapy is hair loss, but many patients and even healthcare professionals don’t know that hair loss from Taxotere can be permanent.

If you or someone you love has experienced permanent chemo hair loss from Taxotere, you may be able to gain some kind of compensation through a breast cancer drug lawsuit.

Filing a Taxotere chemo hair loss risk lawsuit cannot take away the pain and suffering a cancer patient endures, but it can help compensate for the financial expenses incurred by medical bills or even lost wages.

The Chemo Hair Loss Lawsuit is Case No. 2:17-cv-00988, in the U.S. District Court for the Eastern District of Louisiana.